To add a bio or update investment portfolio click update information.
LifeArc Ventures: Investment Portfolio & Startup News
LifeArc Ventures
Investment Portfolio
RQ Bio
25 Jun 2026
RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza
RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza. Its lead programme, RQB01, is designed to deliver potent, broad-strain protection against influenza through a dual mechanism of action, targeting patients whose immune systems cannot rely on vaccination alone.
Cytospire Therapeutics
5 May 2026
Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.
LifeArc Ventures
More venture news
- 29 Sept 2026
DYADDYAD secures a £7.5m Series A led by Sangha Capital for its system that converts clinical documents into structured data for GP patient records
Series AHealth - 21 Sept 2026
SpriveSprive unlocks an £8m Series A from VCs to help homeowners pay down their mortgages
Series AFintech - 17 Sept 2026
MagenticMagentic closes £13m Series A led by Felicis to put AI workers inside the procurement teams of global manufacturers
Series ASupply Chain
